Tag: Biophytis
Biophytis: A patent application filed in obesity
Read also (CercleFinance.com) – The biotechnology company Biophytis rose by almost 4% Monday morning on the Paris Stock Exchange after announcing the filing of a patent application in obesity, a…
Biophytis: For patients undergoing anti-obesity treatment, Biophytis aims to combat muscle loss
(BFM Bourse) – The biotechnology company is soaring on the Paris Stock Exchange, after unveiling a clinical program aimed at combating muscle loss associated with anti-obesity treatments. Along with artificial…
Biophytis launches phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone) – 04/08/2024 at 11:14 p.m.
Paris, France, Cambridge (Massachusetts, United States), April 8, 2024 – 11:00 p.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company clinical…
Biophytis announces its 2023 financial results and provides an update on its activities – 04/08/2024 at 11:16 p.m.
Biophytis announces its 2023 financial results and provides an update on its activities Paris (France) and Cambridge (Massachusetts, United States), April 8, 2024 – 11:00 p.m. – Biophytis SA (Nasdaq…
Biophytis announces the launch of the consolidation of the shares making up its share capital – 03/15/2024 at 11:00 p.m.
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative…
Biophytis presented the potential of RuvembriTM in the treatment of Duchenne muscular dystrophy – 03/08/2024 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative…
Biophytis announces its participation in several conferences in Europe and the United States during the first quarter of 2024 – 11/12/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative…
Biophytis: Sarconeos explored in seasonal influenza – 04/12/2023 at 11:12
(CercleFinance.com) – Biophytis rose on the Paris Stock Exchange on Monday after announcing its intention to explore the potential of Sarconeos, its small molecule, in the treatment of viral respiratory…
Biophytis appoints Yann Meunier and Bernard Lévy to its scientific committee – 11/27/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative…
Biophytis announces the success of its capital increase with maintenance of preferential subscription rights for an amount of approximately €1.96 million – 11/20/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to aging…
Biophytis: no longer meets Nasdaq listing requirements
By Alexandra Saintpierre Published on 11/18/2023 at 4:44 p.m. (Boursier.com) — Biophytis SA has received a “Letter of…
Biophytis receives notification from Nasdaq – 11/17/2023 at 11:00 p.m.
Biophytis SA, a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional outcomes of patients suffering…